Roquefort Therapeutics PLC Restoration of Trading (9549B)
07 Junio 2023 - 4:11AM
UK Regulatory
TIDMROQ
RNS Number : 9549B
Roquefort Therapeutics PLC
07 June 2023
7 June 2023
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Restoration of Trading
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market
listed biotech company focused on developing first in class
medicines in the high value and high growth oncology market ,
advises that following the publication of the Company's 2022 Annual
Report on 5 June 2023 and an application by the Company for the
suspension to be lifted, the Company's shares will be restored to
the Official List and to trading on the London Stock Exchange
today.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN
ARTICLE 7 OF THE MARKET ABUSE REGULATION EU NO. 596/2014, AS
RETAINED AND APPLICABLE IN THE UK PURSUANT TO THE EUROPEAN UNION
(WITHDRAWAL) ACT 2018 ("MAR"). UPON THE PUBLICATION OF THIS
ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN
THE PUBLIC DOMAIN.
-ENDS-
Enquiries:
Roquefort Therapeutics plc
Stephen West (Chairman) / Ajan +44 (0)20 3290
Reginald (CEO) 9339
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Optiva Securities Limited (Joint +44 (0)203 764
Broker) 2341
+44 (0)20 3411
Christian Dennis 1881
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George +44 (0)20 7466
Beale 5000
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market
listed biotech company developing first in class drugs in the high
value and high growth oncology segment prior to partnering or
selling to big pharma.
Since listing in March 2021, Roquefort Therapeutics has
successfully acquired Lyramid Pty Limited, a leader in the
development of medicines for a new therapeutic target, Midkine (a
human growth factor associated with cancer progression), and most
recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor
Sir Martin Evans, which has developed two families of innovative
cell and RNA oncology medicines.
Roquefort Therapeutics' portfolio consists of five fully funded,
novel patent-protected pre-clinical anti-cancer medicines. The
highly complementary profile of five best-in-class medicines
consists of:
-- Midkine antibodies with significant in vivo efficacy and toxicology studies;
-- Midkine RNA therapeutics with novel anti-cancer gene editing action;
-- Midkine mRNA therapeutics with novel anti-cancer approach;
-- STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
-- MK cell therapy with direct and NK-mediated anti-cancer action
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RENNKOBKCBKKFAK
(END) Dow Jones Newswires
June 07, 2023 05:11 ET (09:11 GMT)
Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Roquefort Therapeutics (LSE:ROQ)
Gráfica de Acción Histórica
De May 2023 a May 2024